Biology of thrombopoietin

Current Opinion in Pediatrics

Volumn 10, Issue 1, 1998, Pages 60-64

  Broudy, Virginia C ^a   Kaushansky, Kenneth ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; THROMBOPOIETIN;

HEMATOPOIESIS; HUMAN; MEGAKARYOPOIESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD PLATELETS; HEMATOPOIESIS; HUMANS; LIVER; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THROMBOPOIETIN;

EID: 0031900406     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199802000-00012     Document Type: Review

References (36)

1. Vigon I, Mornon J-P, Cocault L, Mitjavila M-T, Tambourin P, Gisselbrecht S, Souyri M: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 1992, 89:5640-6544.
2. Methia N, Louache F, Vainchenker W, Wendling F: Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993, 82:1395-1401.
3. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Hanzel WJ, Wong SC, Kuang W-J, et al.: Stimulation of megakaryocytopoiesis and thrombopoiesis by the C-Mpl ligand. Nature 1994, 369:533-538.
4. Lok S, Kaushansky K, Holly RD, Kuljper JL, Lofton-Day CE, Oort PJ, Grant FJ, Helpel MD, Burkhead SK, Kramer JM, et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994, 369:565-568.
5. Bartley TD, Bogenberger J, Hunt P, Li Y-S, Lu HS, Martin F, Chang M-S, Samal B, Nichol JL, Swift S, et al.: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77:1117-1124.
6. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994, 91:11104-11108.
7. Sohma Y, Akahori H, Seki N, Hori T-A, Ogami K, Kato T, Shimada Y, Kawamura K, Miyazaki H: Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994, 353:57-61.
8. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tnasik RL, Mattheakis LC, Boytos CM, et al.: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276:1696-1699.
9. Kuter DJ, Rosenberg RD: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995, 85:2720-2730.
10. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K: Human platelets display high-affinity receptors for thrombopoietin. Blood 1997, 89:1896-1904.
11. Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller G-A, de Sauvage FJ, Eaton D: Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997, 89:2782-2788.
12. Shivdasani RA, Fielder P, Keller G-A, Orkin SH, de Sauvage FJ: Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice. Blood 1997, 90:1821-1827.
13. Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87:4068-4071.
14. Chang M, Suen Y, Meng G, Buzby JS, Bussel J, Shen V, van de Ven C, Cairo MS: Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996, 88:3354-3362.
15. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA: Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997, 127:285-288.
16. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW: Thrombocytopenia in c-mpl-deficient mice. Science 1994, 265:1445-1447.
17. Carver-Moore K, Broxmeyer HE, Luoh S-M, Cooper S, Peng J, Burstein SA, Moore MW, de Sauvage FJ: Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996, 88:803-808.
18. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood 1996, 87:2162-2170.
19. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, Bailey M, Papayannopoulou T, Forstrom JW, Sprugel KH: Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995, 96:1683-1687.
20. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC: Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996, 24:265-269.
21. Neelis KJ, Qingliang L, Thomas GR, Cohen BL, Eaton DL, Wagemaker G: Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. Blood 1997, 90:58-63. This article shows that treatment with rhTPO enhanced platelet recovery in myelosuppressed primates. As would have been predicted from the studies of myelosuppressed mice treated with thrombopoietin, rhTPO also stimulated erythropoiesis in vivo. However, the effect of rhTPO on erythropoiesis in the primates was curbed by the development of functional iron deficiency.
22. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987, 316:73-78.
23. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, et al.: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in cancer patients. Ann Intern Med 1997, 126:673-681. In the patients in this study, the platelet count began to rise at day 4 and peaked at day 12 after a single dose of rhTPO. Multiple classes of progenitor cells were mobilized into the blood. The half-life of rhTPO in vivo was long: 20 to 30 hours.
24. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, et al.: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996, 348:1279-1281.
25. O'Malley CJ, Rasko JEJ, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, et al.: Administration of pegylated human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996, 88:3288-3298.
26. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheriday W, Menchaca D, Tomita D, Ozer H, Harker L: Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336:404-409. This randomized double-bund placebo-controlled dose escalation trial of PEG-rHuMGDF in patients undergoing chemotherapy for lung cancer showed that administration of PEG-rHuMGDF raised the nadir platelet count and hastened platelet recovery to baseline levels in comparison to the placebo-treated patients.
27. Basser RL, Rasko J, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, et al.: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997, 89:3118-3128. Patients with solid tumors being treated with a myelosuppressive chemotherapy regimen were randomly selected to receive PEG-rHuMGDF plus granulocyte colony-stimulating factor, or placebo plus granulocyte colony-stimulating factor. The addition of PEG-rHuMGDF accelerated platelet recovery to baseline values, and increased mobilization of primitive hematopoietic progenitor cells into the blood.
28. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y: Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996, 87:4664-4670.
29. Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC: Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol 1997, 54:225-232.
30. Basser R, De Boer R, Mitchell P, Green M, Zalcberg J, Cebon J, Renwick J, Cohen B, Menchaca D, LaBrecque J, Fox R, Begley G: Randomized study of megakaryocyte growth and development factor (PEG-rHuMGDF) before and after chemotherapy: influence of schedule on clinical effect Early results [abstract]. Proc Am Soc Clin Oncol 1997, 16:120a.
31. Ku H, Yonemura Y, Kaushansky K, Ogawa M: Thrombopoietin, the ligand for the Mpl receptor, synergy with steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996, 87:4544-4551.
32. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, Kaushansky K: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996, 87:4998-5005.
33. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M: Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997, 89:2644-2653. Human cord blood cells were cultured in the presence of FLT3 ligand plus thrombopoietin in vitro. The numbers of CFU-GM were expanded more than 2 million fold during the 6-month culture period. If it can be demonstrated that stem cells are also expanded, this approach may eventually prove useful for cord blood transplantation programs.
34. Farese AM, Hunt P, Grab LB, MacVittae TJ: Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multi-lineage hematopoietic reconstitution in nonhuman primates after radiation induced marrow aplasia. J Clin Invest 1996, 97:2145-2151.
35. Molineaux G, Hartley C, McElroy P, McCrea C, McNiece IK: Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 1996, 88:366-376.
36. Bertolini F, Battaglia M, Pedrazzoli P, Da Prada GA, Lanza A, Soligo D, Caneve L, Sarina B, Murphy S, Thomas T, della Cuna GR: Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997, 89:2679-2688. Human C034+ peripheral blood progenitor cells were cultured in the presence of a cocktail of cytokines including thrombopoietin, then infused into patients undergoing autologous peripheral blood stem cell transplantation. The infusion of the ex vivo-generated megakaryocytes was safe. Whether this approach will decrease the need for platelet transfusions remains to be determined.